Clinical Trials
12 trialsNCT06393751 2025-06-03
Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT03647423 2025-02-21
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT05042934 2022-02-10
Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT05080621 2022-01-05
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
Deciphera Pharmaceuticals, LLC
Phase 1/2 Withdrawn
NCT04648826 2021-12-17
Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT01415765 2019-12-17
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT01740570 2018-01-19
Phase I/II Cabazitaxel for Recurrent Malignant Glioma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT02229981 2017-12-07
ABC-102
RedHill Biopharma Limited
Phase 1/2 Withdrawn
NCT02521090 2016-02-15
EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Withdrawn
NCT01174537 2015-06-11
New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma
Hadassah Medical Organization
Phase 1/2 Withdrawn
NCT00021307 2013-07-11
Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme
Fox Chase Cancer Center
Phase 1/2 Withdrawn